false
0001326706
0001326706
2025-07-11
2025-07-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 11, 2025
NanoVibronix,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-36445 |
|
01-0801232 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
969
Pruitt Ave
Tyler,
Texas |
|
77569 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (914) 233-3004
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
NAOV |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
On
July 11, 2025, NanoVibronix, Inc. (the “Company”) opened and adjourned its Special Meeting of Stockholders
(the “Special Meeting”) due to an absence of a quorum in accordance with the Company’s Amended and Restated
Bylaws, as amended, without any business being conducted. The Special Meeting will be reconvened virtually with respect to all proposals
at 10:00 a.m. Eastern Time on Thursday, July 17, 2025 (the “Reconvened Special Meeting”), at www.virtualshareholdermeeting.com/NAOV2025SM2.
The record date for determining shareholders eligible to vote at the Reconvened Special Meeting remains unchanged as the close of business
on May 16, 2025 (the “Record Date”).
The
new proxy deadline date for the Reconvened Special Meeting is 11:59 p.m. Eastern Time on July 16, 2025, for shares held directly. Proxies
deposited to date will remain valid for the Reconvened Special Meeting. Any shareholders who have not already voted can also vote prior
to the new proxy deadline date or online at the Reconvened Special Meeting. Stockholders who have already duly submitted voting instructions
for the Special Meeting do not need to take any further action unless they wish to change or revoke their vote.
Additional
Information and Where to Find It
The
Company has filed with the Securities and Exchange Commission (the “SEC”) on June 20, 2025, a Definitive Proxy
Statement (the “Proxy Statement”) in connection with the Special Meeting, and has mailed the Proxy Statement
to its stockholders of record as of the Record Date. Investors and security holders of the Company are advised to read the Proxy Statement
and any supplements and amendments thereto, because these documents contain important information about the Meeting and the Company.
Stockholders will also be able to obtain copies of the Proxy Statement, without charge, as set forth in the Proxy Statement.
Participants
in the Solicitation
The
Company and its directors and executive officers may be considered participants in the solicitation of proxies with respect to the Meeting
under the rules of the SEC. Information about the directors and executive officers of the Company and a description of their interests
in the Company are set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed
with the SEC on March 31, 2025 (the “Annual Report”), and the Proxy Statement, which was filed with the SEC
on June 20, 2025. These documents can be obtained free of charge as set forth in the Proxy Statement.
Forward-Looking
Statements
Certain
statements made in this Current Report are “forward looking statements” within the meaning of the “safe harbor”
provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees
of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important
factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from
those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include:
the inability of the Company to consummate a business combination within the time provided in the Company’s amended and restated
memorandum and articles of association; the level of redemptions made by the Company’s shareholders in connection with the Meeting
and its impact on the amount of funds available in the Company’s trust account to complete an initial business combination; and
those factors discussed in the Annual Report under the heading “Risk Factors,” and other documents of the Company filed,
or to be filed, with the SEC. The Company does not undertake any obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except as required by law.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Date:
July 11, 2025 |
NANOVIBRONIX,
Inc. |
|
|
|
By: |
/s/
Stephen Brown |
|
Name: |
Stephen Brown |
|
Title: |
Chief
Financial Officer |